Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #238131 on Biotech Values
DewDiligence
12/30/21 7:09 PM
#241036 RE: DewDiligence #238131
Xeris Biopharma Holdings…today announced the U.S. Food and Drug Administration (FDA) approval of Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.